Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PTPRC_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PTPRC_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTPRC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTPRC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTPRC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000191612 | Cervix | N_HPV | positive regulation of T cell mediated cytotoxicity | 7/534 | 29/18723 | 1.33e-05 | 4.27e-04 | 7 |
GO:200123524 | Cervix | N_HPV | positive regulation of apoptotic signaling pathway | 14/534 | 126/18723 | 1.47e-05 | 4.55e-04 | 14 |
GO:003134111 | Cervix | N_HPV | regulation of cell killing | 12/534 | 99/18723 | 2.48e-05 | 6.77e-04 | 12 |
GO:000225321 | Cervix | N_HPV | activation of immune response | 26/534 | 375/18723 | 3.06e-05 | 8.02e-04 | 26 |
GO:00026972 | Cervix | N_HPV | regulation of immune effector process | 24/534 | 339/18723 | 4.42e-05 | 1.04e-03 | 24 |
GO:00017741 | Cervix | N_HPV | microglial cell activation | 8/534 | 47/18723 | 4.90e-05 | 1.13e-03 | 8 |
GO:007149624 | Cervix | N_HPV | cellular response to external stimulus | 23/534 | 320/18723 | 5.03e-05 | 1.15e-03 | 23 |
GO:00430302 | Cervix | N_HPV | regulation of macrophage activation | 9/534 | 61/18723 | 5.41e-05 | 1.22e-03 | 9 |
GO:000190911 | Cervix | N_HPV | leukocyte mediated cytotoxicity | 13/534 | 124/18723 | 5.46e-05 | 1.22e-03 | 13 |
GO:003157912 | Cervix | N_HPV | membrane raft organization | 6/534 | 25/18723 | 5.84e-05 | 1.28e-03 | 6 |
GO:000716222 | Cervix | N_HPV | negative regulation of cell adhesion | 22/534 | 303/18723 | 6.28e-05 | 1.37e-03 | 22 |
GO:00028192 | Cervix | N_HPV | regulation of adaptive immune response | 16/534 | 183/18723 | 7.36e-05 | 1.59e-03 | 16 |
GO:0002703 | Cervix | N_HPV | regulation of leukocyte mediated immunity | 18/534 | 226/18723 | 9.00e-05 | 1.86e-03 | 18 |
GO:003270311 | Cervix | N_HPV | negative regulation of interleukin-2 production | 6/534 | 27/18723 | 9.30e-05 | 1.91e-03 | 6 |
GO:00028222 | Cervix | N_HPV | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 15/534 | 168/18723 | 9.68e-05 | 1.97e-03 | 15 |
GO:000191412 | Cervix | N_HPV | regulation of T cell mediated cytotoxicity | 7/534 | 39/18723 | 1.03e-04 | 2.06e-03 | 7 |
GO:00027682 | Cervix | N_HPV | immune response-regulating cell surface receptor signaling pathway | 22/534 | 315/18723 | 1.11e-04 | 2.18e-03 | 22 |
GO:00313422 | Cervix | N_HPV | negative regulation of cell killing | 6/534 | 28/18723 | 1.15e-04 | 2.26e-03 | 6 |
GO:0002705 | Cervix | N_HPV | positive regulation of leukocyte mediated immunity | 13/534 | 134/18723 | 1.21e-04 | 2.33e-03 | 13 |
GO:00022632 | Cervix | N_HPV | cell activation involved in immune response | 20/534 | 279/18723 | 1.59e-04 | 2.82e-03 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTPRC | SNV | Missense_Mutation | | c.794N>A | p.Cys265Tyr | p.C265Y | | protein_coding | tolerated(0.08) | possibly_damaging(0.9) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | | c.2299N>T | p.Pro767Ser | p.P767S | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | | c.448N>A | p.Gly150Arg | p.G150R | | protein_coding | tolerated(0.11) | possibly_damaging(0.486) | TCGA-AC-A2FM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PTPRC | SNV | Missense_Mutation | novel | c.977A>C | p.Lys326Thr | p.K326T | | protein_coding | tolerated(0.35) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | novel | c.319N>T | p.Pro107Ser | p.P107S | | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | | c.1538N>A | p.Gly513Asp | p.G513D | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PTPRC | SNV | Missense_Mutation | rs758824419 | c.2695N>A | p.Glu899Lys | p.E899K | | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PTPRC | SNV | Missense_Mutation | novel | c.2476N>C | p.Glu826Gln | p.E826Q | | protein_coding | deleterious(0.01) | possibly_damaging(0.669) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
PTPRC | SNV | Missense_Mutation | | c.3337N>A | p.Asp1113Asn | p.D1113N | | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PTPRC | SNV | Missense_Mutation | | c.308N>T | p.Ser103Leu | p.S103L | | protein_coding | tolerated(0.73) | benign(0.084) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | [131I]-BC8 | | |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | HYDROGEN PEROXIDE | HYDROGEN PEROXIDE | 15012988 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | PREDNISONE | PREDNISONE | 17063711 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | ERYTHROPOIETIN | EPOETIN BETA | 1713254 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | GM-CSF/IL-3 FUSION PROTEIN | | 1713254 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | etanercept | ETANERCEPT | 20309874,23007924 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | VACCINE | | 12007880 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | adalimumab | ADALIMUMAB | 20309874,23007924 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | PROTEIN KINASE INHIBITOR | | 9473774 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | LM-CD45 | | |